Valuation : HLS Therapeutics Inc.

Market Cap 84.39M 72.85M 68.28M 62.35M 117M 8.05B 118M 809M 316M 4.07B 317M 310M 13.51B P/E 2026 *
-13.2x
P/E 2027 * -39x
Enterprise Value 84.39M 72.85M 68.28M 62.35M 117M 8.05B 118M 809M 316M 4.07B 317M 310M 13.51B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.3x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day+2.43%
1 week+1.07%
Current month-9.76%
1 month-10.82%
3 months-17.43%
6 months-15.78%
Current year-21.37%
1 week 3.64
Extreme 3.64
3.92
1 month 3.56
Extreme 3.56
4.29
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Buy

Chief Executive Officer

500 0.0016%
17/08/26 Buy

Chief Executive Officer

2,000 0.0064%
31/07/26 TaxCompany 1,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+2.43%+1.07%-29.29%-13.86% 84.39M
+0.32%+4.02%+30.11%+111.86% 104B
-0.25%+2.20%+57.65%+161.10% 54.55B
+2.29%-7.59%-14.10%+239.24% 22.12B
+0.86%+1.36%-12.10%-14.93% 8.15B
-0.07%-1.57%-37.56%-28.02% 7.21B
-1.05%+0.93%+2.68%+18.68% 6.36B
+0.76%-4.32%-14.68%-30.59% 6.34B
+0.54%+2.93%-1.58%+21.54% 5.2B
+2.78%+16.03%+284.53%+455.00% 4.29B
Average +0.86%+2.07%+26.57%+92.00% 21.85B
Weighted average by Cap. +0.41%+3.12%+30.82%+125.39%

Financials

2026 *2027 *
Net sales 58.44M 50.45M 47.29M 43.18M 81.25M 5.57B 81.61M 561M 219M 2.82B 219M 215M 9.36B 65.03M 56.14M 52.62M 48.04M 90.41M 6.2B 90.8M 624M 244M 3.14B 244M 239M 10.41B
Net income -5.47M -4.72M -4.43M -4.04M -7.6M -522M -7.64M -52.46M -20.49M -264M -20.53M -20.09M -876M -2.16M -1.87M -1.75M -1.6M -3.01M -206M -3.02M -20.76M -8.11M -104M -8.13M -7.95M -347M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
28/08/26 CA$3.790 +2.43% 52,047
27/08/26 CA$3.700 +1.37% 34,900
26/08/26 CA$3.650 -4.95% 17,582
25/08/26 CA$3.840 +4.07% 36,505
24/08/26 CA$3.690 -1.60% 113,781
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.728USD
Average target price
5.286USD
Spread / Average Target
+93.78%

Quarterly revenue - Rate of surprise